These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22421947)

  • 1. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.
    Bao L; Cowan MJ; Dunham K; Horn B; McGuirk J; Gilman A; Lucas KG
    J Immunother; 2012 Apr; 35(3):293-8. PubMed ID: 22421947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
    Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.
    Horn B; Bao L; Dunham K; Stamer M; Adler S; Cowan M; Lucas K
    Pediatr Infect Dis J; 2009 Jan; 28(1):65-7. PubMed ID: 19034064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.
    Cwynarski K; Ainsworth J; Cobbold M; Wagner S; Mahendra P; Apperley J; Goldman J; Craddock C; Moss PA
    Blood; 2001 Mar; 97(5):1232-40. PubMed ID: 11222365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
    Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
    Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.
    Feuchtinger T; Opherk K; Bethge WA; Topp MS; Schuster FR; Weissinger EM; Mohty M; Or R; Maschan M; Schumm M; Hamprecht K; Handgretinger R; Lang P; Einsele H
    Blood; 2010 Nov; 116(20):4360-7. PubMed ID: 20625005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
    Blyth E; Clancy L; Simms R; Ma CK; Burgess J; Deo S; Byth K; Dubosq MC; Shaw PJ; Micklethwaite KP; Gottlieb DJ
    Blood; 2013 May; 121(18):3745-58. PubMed ID: 23435462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation.
    Pei XY; Liu XF; Zhao XY; Lv M; Mo XD; Chang YJ; Shang QN; Sun YQ; Chen YH; Xu LP; Wang Y; Zhang XH; Liu KY; Huang XJ
    Cell Mol Immunol; 2022 Apr; 19(4):482-491. PubMed ID: 35017718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
    Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
    Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes.
    Watanabe N; Kamachi Y; Koyama N; Hama A; Liang J; Nakamura Y; Yamamoto T; Isomura M; Kudo K; Kuzushima K; Kojima S
    Cytotherapy; 2004; 6(5):514-22. PubMed ID: 15512918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
    Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
    J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
    N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.